Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Status Not yet recruiting

Clinical Trial Summary

Research question: Is KRd therapy effective and safe in the real-world Asian patients? Primay objective: To evaluate the effectiveness of KRd in RRMM patients Secondary objectives: To evaluate the effectiveness of investigational treatment strategy by - PFS difference according to the high-risk disease subgroups and previous treatment - OS - Overall response rate and clinical benefit rate - Duration of response To evaluate the safety and tolerability of KRd in RRMM patients

Clinical Trial Description

Key study variables: Demographic data, ISS, R-ISS, cytogenetic abnormalities on FISH and G-banding, previous treatment regimens, response to previous treatment regimens, existence of extramedullary plasmacytoma, MM-related symptoms, whether or not M protein has increased twice or more in 2-3 months at the time of KRd commencement, response to KRd therapy, duration of KRd treatment, adverse events during KRd therapy, disease progression and progression date, survival, and censored date or day of death ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05495620
Study type	Observational
Source	Dong-A University Hospital
Contact	Ji Hyun Lee, MD, Ph.D
Phone	82-51-240-2915
Email	hidrleejh@dau.ac.kr
Status	Not yet recruiting
Phase
Start date	August 1, 2022
Completion date	September 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01435720` - Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)	Phase 1/Phase 2
Recruiting	`NCT04094961` - Ixazomib + Pomalidomide + Dexamethasone In MM	Phase 1/Phase 2
Recruiting	`NCT06068400` - Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma	N/A
Recruiting	`NCT03601624` - Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans	Phase 2
Recruiting	`NCT05020444` - TriPRIL CAR T Cells in Multiple Myeloma	Phase 1
Not yet recruiting	`NCT03706547` - Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM	Phase 1
Active, not recruiting	`NCT02970747` - Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
Not yet recruiting	`NCT06411301` - A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors	Phase 1
Completed	`NCT01965353` - A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma	Phase 1
Not yet recruiting	`NCT05581875` - A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory	Phase 1/Phase 2
Terminated	`NCT03687125` - Tinostamustine Conditioning and Autologous Stem Cell	Phase 1/Phase 2
Recruiting	`NCT06282978` - Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes	Phase 2
Recruiting	`NCT06158412` - All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma	Phase 2
Active, not recruiting	`NCT03030261` - Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma	Phase 2
Recruiting	`NCT04925193` - Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma	Phase 2
Recruiting	`NCT05121103` - A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma	Phase 1
Recruiting	`NCT04603872` - CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies	Early Phase 1
Recruiting	`NCT04657861` - APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma	Early Phase 1
Terminated	`NCT05191472` - Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies	Phase 2
Completed	`NCT03136653` - A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma	Phase 1/Phase 2